Pittsburgh, Pennsylvania 15213


The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs. In patients with cystic fibrosis (CF), this fungus is not known to cause damage to the lungs, but some patients respond with an allergic reaction that cause them to wheeze, cough, or have difficulty breathing. Approximately 230 patients will be enrolled with an additional 60 people who do not have CF and who do not have a history of asthma to serve as a comparison group.


Inclusion Criteria: (CF) - diagnosis of CF - age 6 years or older - presence of A. fumigatus in culture of airway flora, or the presence of one or more of the diagnostic criteria for ABPA (Control) - age and sex matched to CF population Exclusion Criteria: (CF) - uncontrolled CF-related diabetes mellitus - use of oral steroids at a dose ≥ 0.5 mg/kg/day - history of lung transplantation - pulmonary exacerbation as defined by requirement for use of intravenous antibiotics or need for hospitalization within the preceding 14 days. - patients who have a diagnosis of HIV and have a CD4+ Tcell count below 500 cells/ml will be excluded (control) - asthma



Primary Contact:

Principal Investigator
Jay K Kolls, MD
University of Pittsburgh

Elizabeth R Hartigan, MPH, RN
Phone: 412-692-7060
Email: elizabeth.hartigan@chp.edu

Backup Contact:

Email: adrienne.horn@chp.edu
Adrienne Horn, BSN, RN
Phone: 412-692-8069

Location Contact:

Pittsburgh, Pennsylvania 15213
United States

Elizabeth R Hartigan, MPH, RN
Phone: 412-692-7060
Email: elizabeth.hartigan@chp.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.